@article{deZeeuwAkizawaAgarwaletal.2013, author = {de Zeeuw, Dick and Akizawa, Tadao and Agarwal, Rajiv and Audhya, Paul and Bakris, George L. and Chin, Melanie and Krauth, Melissa and Lambers Heerspink, Hiddo J. and Meyer, Colin J. and McMurray, John J. and Parving, Hans-Henrik and Pergola, Pablo E. and Remuzzi, Giuseppe and Toto, Robert D. and Vaziri, Nosratola D. and Wanner, Christoph and Warnock, David G. and Wittes, Janet and Chertow, Glenn M.}, title = {Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)}, series = {American Journal of Nephrology}, volume = {37}, journal = {American Journal of Nephrology}, number = {3}, issn = {0250-8095}, doi = {10.1159/000346948}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196832}, pages = {212-222}, year = {2013}, abstract = {Background: Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD. Methods: Herein, we describe the design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON) trial, a multinational, multicenter, double-blind, randomized, placebo-controlled Phase 3 trial designed to determine whether long-term administration of bardoxolone methyl (on a background of standard therapy, including RAAS inhibitors) safely reduces renal and cardiac morbidity and mortality. Results: The primary composite endpoint is time-to-first occurrence of either end-stage renal disease or cardiovascular death. Secondary endpoints include the change in eGFR and time to occurrence of cardiovascular events. Conclusion: BEACON will be the first event-driven trial to evaluate the effect of an oral antioxidant and anti-inflammatory drug in advanced CKD.}, language = {en} } @article{KuehnSchoenEdelmannetal.2013, author = {K{\"u}hn, Heike and Sch{\"o}n, Franz and Edelmann, Karola and Brill, Stefan and M{\"u}ller, Joachim}, title = {The Development of Lateralization Abilities in Children with Bilateral Cochlear Implants}, series = {ORL}, volume = {75}, journal = {ORL}, number = {2}, issn = {0301-1569}, doi = {10.1159/000347193}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196375}, pages = {55-67}, year = {2013}, abstract = {Objectives: The purpose of this study was to investigate the development of lateralization skills in children who received bilateral cochlear implants (CIs) in sequential operations. Methods: The lateralization skills of 9 children with a mean age of 4.1 years at the first surgery and 5.5 years at the second surgery were assessed at 3 time intervals. Children were assessed with a 3-loudspeaker setup (front, left and right) at 0.9 years (interval I) and 1.6 years (interval II) after the second implantation, and after 5.3 years of bilateral implant use (interval III) with a 9-loudspeaker setup in the frontal horizontal plane between -90° and 90° azimuth. Results: With bilateral implants, a significant decrease in lateralization error was noted between test interval I (45.0°) and II (23.3°), with a subsequent significant decrease at test interval III (4.7°). Unilateral performance with the CI did not improve significantly between the first 2 intervals; however, there was a bias of responses towards the unilateral side by test interval III. Conclusions: The lateralization abilities of children with bilateral CIs develop in a relatively short period of time (1-2 years) after the second implant. Children appear to be able to acquire binaural skills after bilateral cochlear implantation.}, language = {en} } @article{HeinrichNandaRehnetal.2013, author = {Heinrich, T. and Nanda, I. and Rehn, M. and Zollner, U. and Frieauff, E. and Wirbelauer, J. and Grimm, T. and Schmid, M.}, title = {Live-Born Trisomy 22: Patient Report and Review}, series = {Molecular Syndromology}, volume = {3}, journal = {Molecular Syndromology}, number = {6}, issn = {1661-8769}, doi = {10.1159/000346189}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196535}, pages = {262-269}, year = {2013}, abstract = {Trisomy 22 is a common trisomy in spontaneous abortions. In contrast, live-born trisomy 22 is rarely seen due to severe organ malformations associated with this condition. Here, we report on a male infant with complete, non-mosaic trisomy 22 born at 35 + 5 weeks via caesarean section. Peripheral blood lymphocytes and fibroblasts showed an additional chromosome 22 in all metaphases analyzed (47,XY,+22). In addition, array CGH confirmed complete trisomy 22. The patient's clinical features included dolichocephalus, hypertelorism, flattened nasal bridge, dysplastic ears with preauricular sinuses and tags, medial cleft palate, anal atresia, and coronary hypospadias with scrotum bipartitum. Essential treatment was implemented in close coordination with the parents. The child died 29 days after birth due to respiratory insufficiency and deterioration of renal function. Our patient's history complements other reports illustrating that children with complete trisomy 22 may survive until birth and beyond.}, language = {en} } @article{MatthiesBrillKagaetal.2013, author = {Matthies, Cordula and Brill, Stefan and Kaga, Kimitaka and Morita, Akio and Kumakawa, Kozo and Skarzynski, Henryk and Claassen, Andre and Hui, Yau and Chiong, Charlotte and M{\"u}ller, Joachim and Behr, Robert}, title = {Auditory Brainstem Implantation Improves Speech Recognition in Neurofibromatosis Type II Patients}, series = {ORL}, volume = {75}, journal = {ORL}, number = {5}, issn = {0301-1569}, doi = {10.1159/000350568}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196383}, pages = {282-295}, year = {2013}, abstract = {This prospective study aimed to determine speech understanding in neurofibromatosis type II (NF2) patients following implantation of a MED-EL COMBI 40+ auditory brainstem implant (ABI). Patients (n = 32) were enrolled postsurgically. Nonauditory side effects were evaluated at fitting and audiological performance was determined using the Sound Effects Recognition Test (SERT), Monosyllable-Trochee-Polysyllable (MTP) test and open-set sentence tests. Subjective benefits were determined by questionnaire. ABI activation was documented in 27 patients, 2 patients were too ill for testing and 3 patients were without any auditory perception. SERT and MTP outcomes under auditory-only conditions improved significantly between first fitting and 12-month follow-up. Open-set sentence recognition improved from 5\% at first fitting to 37\% after 12 months. The number of active electrodes had no significant effect on performance. All questionnaire respondents were 'satisfied' to 'very satisfied' with their ABI. An ABI is an effective treatment option in NF2 patients with the potential to provide open-set speech recognition and subjective benefits. To our knowledge, the data presented herein is exceptional in terms of the open-set speech perception achieved in NF2 patients.}, language = {en} } @article{WeberGraef2013, author = {Weber, Christoph and Gr{\"a}f, Stephan}, title = {Eine halb so schlimme T{\"a}uschung}, series = {JURA - Juristische Ausbildung}, volume = {36}, journal = {JURA - Juristische Ausbildung}, number = {1}, issn = {1612-7021}, doi = {10.1515/jura-2014-0009}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-195484}, pages = {81-93}, year = {2013}, abstract = {Kein Abstract verf{\"u}gbar.}, language = {en} } @article{PfisterSchwarzJanczyketal.2013, author = {Pfister, Roland and Schwarz, Katharina A. and Janczyk, Markus and Dale, Rick and Freeman, Jonathan B.}, title = {Good things peak in pairs: a note on the bimodality coefficient}, series = {Frontiers in Psychology}, volume = {4}, journal = {Frontiers in Psychology}, issn = {1664-1078}, doi = {10.3389/fpsyg.2013.00700}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-190413}, year = {2013}, abstract = {A commentary on Assessing bimodality to detect the presence of a dual cognitive process by Freeman, J. B., and Dale, R. (2013). Behav. Res. Methods 45, 83-97. doi: 10.3758/s13428-012-0225-x}, language = {en} } @article{FoersterPfisterSchmidtsetal.2013, author = {Foerster, Anna and Pfister, Roland and Schmidts, Constantin and Dignath, David and Kunde, Wilfried}, title = {Honesty saves time (and justifications)}, series = {Frontiers in Psychology}, volume = {4}, journal = {Frontiers in Psychology}, issn = {1664-1078}, doi = {10.3389/fpsyg.2013.00473}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-190451}, year = {2013}, abstract = {A commentary on Honesty requires time (and lack of justifications) by Shalvi, S., Eldar, O., and Bereby-Meyer, Y. (2012). Psychol. Sci. 23, 1264-1270. doi: 10.1177/0956797612443835}, language = {en} } @article{MeuleVoegele2013, author = {Meule, Adrian and V{\"o}gele, Claus}, title = {The psychology of eating}, series = {Frontiers in Psychology}, volume = {4}, journal = {Frontiers in Psychology}, issn = {1664-1078}, doi = {10.3389/fpsyg.2013.00215}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-190460}, year = {2013}, abstract = {No abstract available.}, language = {en} } @article{Meule2013, author = {Meule, Adrian}, title = {Impulsivity and overeating: a closer look at the subscales of the Barratt Impulsiveness Scale}, series = {Frontiers in Psychology}, volume = {4}, journal = {Frontiers in Psychology}, issn = {1664-1078}, doi = {10.3389/fpsyg.2013.00177}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-190497}, year = {2013}, abstract = {No abstract available.}, language = {en} } @article{KressHuettenhoferLandryetal.2013, author = {Kress, Michaela and H{\"u}ttenhofer, Alexander and Landry, Marc and Kuner, Rohini and Favereaux, Alexandre and Greenberg, David and Bednarik, Josef and Heppenstall, Paul and Kronenberg, Florian and Malcangio, Marzia and Rittner, Heike and {\"U}{\c{c}}eyler, Nurcan and Trajanoski, Zlatko and Mouritzen, Peter and Birklein, Frank and Sommer, Claudia and Soreq, Hermona}, title = {microRNAs in nociceptive circuits as predictors of future clinical applications}, series = {Frontiers in Molecular Neuroscience}, volume = {6}, journal = {Frontiers in Molecular Neuroscience}, number = {33}, doi = {10.3389/fnmol.2013.00033}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-154597}, year = {2013}, abstract = {Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain, and non-coding RNAs - and microRNAs (miRNAs) in particular - regulate both immune and neuronal processes. Specifically, miRNAs control macromolecular complexes in neurons, glia and immune cells and regulate signals used for neuro-immune communication in the pain pathway. Therefore, miRNAs may be hypothesized as critically important master switches modulating chronic pain. In particular, understanding the concerted function of miRNA in the regulation of nociception and endogenous analgesia and defining the importance of miRNAs in the circuitries and cognitive, emotional and behavioral components involved in pain is expected to shed new light on the enigmatic pathophysiology of neuropathic pain, migraine and complex regional pain syndrome. Specific miRNAs may evolve as new druggable molecular targets for pain prevention and relief. Furthermore, predisposing miRNA expression patterns and inter-individual variations and polymorphisms in miRNAs and/or their binding sites may serve as biomarkers for pain and help to predict individual risks for certain types of pain and responsiveness to analgesic drugs. miRNA-based diagnostics are expected to develop into hands-on tools that allow better patient stratification, improved mechanism-based treatment, and targeted prevention strategies for high risk individuals.}, language = {en} }